The company made an upfront payment and will provide success-based milestones and royalties in exchange for global rights.

A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Pipedrive, the easy and effective sales CRM for small businesses, today announced the winners of its 2024 Partner Awards, recognizing outstanding contributions from partners who have demonstrated ...

Kinaxis® , a global leader in end-to-end supply chain orchestration, has entered into a settlement agreement with Blue Yonder Group, Inc. to fully resolve all pending litigation matters between the ...

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, ...

The past few weeks were slow when it came to big rounds, but this week was quite the bounce-back. More than a half dozen ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...